Activating transcription factor 3-activated long noncoding RNA forkhead box P4-antisense RNA 1 aggravates colorectal cancer progression by regulating microRNA-423-5p/nucleus accumbens associated 1 axis

Zhuyang Cheng, Song Jiang, Ran Tao, Haipeng Ge, and Jun Qin

Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, JS, China

ABSTRACT

Long noncoding RNAs (IncRNAs) have vital roles in the progression of colorectal cancer (CRC). Forkhead box P4-antisense RNA 1 (FOXP4-AS1) showed a potential unfavorable prognostic factor for CRC, while its underlying mechanism remains elusive. Thus, the goal of this research is to determine mechanism of FOXP4-AS1 in CRC occurrence and development. Herein, a Dual-luciferase reporter assay was performed to assess the regulation of miR-423-5p to nucleus accumbens-associated protein 1 (NACC1) and activating transcription factor 3 (ATF3) to FOXP4-AS1 promoter. Hematoxylin-eosin (H&E) staining was performed to detect the pathological changes of tumor tissues. Flow cytometry, cell counting kit 8, Transwell, and wound healing assays were conducted to assess apoptosis, proliferation, migration, and invasion of CRC cells, respectively. The results showed that FOXP4-AS1 was highly expressed in CRC cell lines and tissues. CRC progression was promoted by the overexpression of FOXP4-AS1 in HCT116 cells and animal models. Furthermore, FOXP4-AS1 served as a molecular sponge for miR-423-5p, and NACC1 is a direct target of miR-423-5p. MiR-423-5p silencing or overexpression of NACC1 increased proliferation, migration, and invasion of HCT116 cells while suppressing apoptosis. We also found that the upregulation of FOXP4-AS1 was activated by ATF3 in CRC cells. Collectively, our results demonstrated that ATF3-activated FOXP4-AS1 aggravates CRC progression by regulating miR-423-5p/NACC1 axis, indicating a new target for CRC treatment.
Introduction

Colorectal cancer (CRC) is currently one of the malignant tumors with a high incidence worldwide. It has an insidious onset, nonspecific early symptoms, a poor prognosis for advanced patients, and a gradual increase in mortality, posing a considerable threat to human health [1]. The diagnosis and treatment of patients with colorectal cancer have advanced significantly during the last two decades. Comprehensive treatment for CRC is based on surgery, supplemented by radiotherapy, chemotherapy, and targeted therapy [2]. However, the recurrence and mortality of patients with CRC have not been significantly improved. Therefore, studies on the development and progression of colorectal cancer and its potential molecular mechanism have tremendous significance for the treatment of CRC.

The occurrence of CRC is affected by many factors such as diet, lifestyle, and genetic characteristics and is the outcome of the interaction of genetic and environmental variables. Long non-coding RNA (lncRNA) exceeds 200 nucleotides in length and is incapable of encoding proteins [3]. LncRNAs participate in various biological functions such as proliferation and differentiation of cells, ontogeny, signal transduction, stem cell maintenance, transcriptional regulation, and post-translational modification [4,5]. Compared with genes encoding proteins, lncRNAs have more substantial temporal and spatial specificity and are closely related to the occurrence and development of diseases. Increasing evidence has indicated the significance of lncRNAs in the development of CRC [6]. As Wang X et al. revealed, small nucleolar RNA host gene 6 is upregulated in CRC tissues and promotes CRC progression by inducing epithelial-mesenchymal transition process and activating the TGF-beta/Smad signaling pathway [7]. Ni W et al. showed that downregulation of growth-arrest-specific transcript 5 by YTH N6-methyladenosine RNA binding protein 3 inhibited proliferation, invasion, and migration of CRC by phosphorylating Yes1 associated transcriptional regulator [8]. In addition, several lncRNAs were identified as biomarkers for the diagnosis and prognosis of CRC, such as small nucleolar RNA host gene 11, urothelial carcinoma associated 1, and prostate cancer associated transcript 1 [9–12]. These finds suggest that lncRNAs are involved in CRC progression by regulating various biological processes. The regulatory mechanisms of other lncRNAs in CRC, however, are elusive. Moreover, lncRNAs have been identified to serve as the competitive endogenous RNAs (ceRNAs) in CRC by binding with microRNAs (miRNAs) to stabilize mRNAs [13–15].

Previous study by Ghasemi T et al. observed the differentially expressed lncRNAs in CRC samples by analyzing three microarray datasets in silico [16]. FOXP4-AS1 has high log fold changes among these lncRNAs. Only two lncRNAs, colorectal neoplasia differentially expressed (CRNDE) and urothelial cancer-associated 1 (UCA1), have higher fold changes than FOXP4-AS1. However, CRNDE and UCA1 were widely studied in CRC. To study them in CRC may lose the novelty. Moreover, we are interested in FOXP4-AS1 since it is an antisense RNA of FOXP4. Our future study will focus on the relationship between FOXP4-AS1 and FOXP4 in CRC. In addition, two studies revealed that FOXP4-AS1 is an unfavorable prognostic factor for CRC [17,18]. However, the underlying mechanism of FOXP4-AS1 in CRC remains largely unknown. We hypothesized that FOXP4-AS1 exerts its function in CRC by the ceRNA pathway. The aim of this research is to investigate the underlying ceRNA mechanism of FOXP4-AS1 in CRC, which could lead to a new treatment target for CRC.

Materials and methods

Patient and tissue samples

Thirty-eight paired CRC tissues and adjacent tissues (with a 5-cm distance from the tumor margin) were obtained from thirty-eight patients diagnosed with CRC at the Affiliated Hospital of Nantong University. All specimens were collected during surgical resection. Patients had not undergone radiotherapy or chemotherapy. Among the 38 CRC patients, 22 were males and 16 were females with an average age of 54 years and age range of 29–78 years. Microscopically, 14 were poorly differentiated, 18 were moderately differentiated, and 6 were well differentiated. Eleven patients presented with
regional lymph node metastasis. The Ethics Committee approved the present study of the Affiliated Hospital of Nantong University. Each patient was informed and had signed an informed consent form.

Cell culture and treatment

FHC, a human normal colonic epithelial cell line, and the CRC cell lines HT29, SW620, SW480, LOVO, and HCT116 were obtained from ATCC and cultured in DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C in an ambient incubator containing 5% CO₂.

Cell transfection and infection

FOXP4-AS1 or nucleus accumbens-associated protein 1 (NACC1) overexpressing or silencing vectors (pcDNA3.1-FOXP4-AS1/NACC1 or sh-FOXP4-AS1/NACC1) with empty pcDNA3.1 vector or sh-NC as the controls were purchased from GenePharma (Shanghai, China). MiR-423-5p mimic or miR-423-5p inhibitor (both from GenePharma) were used for enhancing or silencing endogenous miR-423-5p expression in cancer cells. In 6-well plates, HCT116 cells were seeded and cultured for 12 hours. Using Lipofectamine 3000 transfection reagent (Invitrogen), cells were transfected with FOXP4-AS1, miR-423-5p, and NACC1 according to the manufacturer’s protocols. After 48 hours of transfection, cells were collected for in vitro experiments. Sequences of FOXP4-AS1, miR-423-5p, NACC1, sh-FOXP4-AS1, miR-423-5p mimics/inhibitor, and sh-NACC1 were provided in Supplementary file 1.

The lentivirus vector (pGLVU6/GFP) expressing FOXP4-AS1 or sh-FOXP4-AS1 were packaged by Genepharma with the empty vector as the control. HCT116 cells were infected with these lentivirus vectors (multiplicity of infection: 3) for 4 h and then the medium was replaced according to the manufacturer’s protocols. The infected cells were used for animal experiments at 48 h after infection.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted with TRIzol reagent with DNase, and the concentration of RNA was determined using an Agilent 2100 Bioanalyzer (Agilent). Reverse transcription of 500 ng of RNA into cDNA was performed using a miRNA-specific miRNA assay or an mRNA assay kit (Applied Biosystems). Following that, qRT-PCR was conducted using SYBR® Premix Ex TaqTMii on a CFX 96 real-time PCR thermocycler. GAPDH and U6 were utilized as internal controls for the measurement of mRNA and miRNA expression. The 2−ΔΔCt method [19] was used to determine the relative expression of mRNAs and miRNAs. The following conditions were used in the qRT-PCR reaction: 10 minutes at 92°C, followed by 40 cycles at 92°C for 10 seconds and 60°C for 1 minute. The primers used during this study were as follows: FOXP4-AS1: F, 5′-GTGAGGCTCTGGGGTCGACA-3′; R: 5′-ATTGAGGTTAGGGCAGCAG-3′; miR-4999-5p: F: 5′-GTGAGATCGGAACTACGTG-3′, R: 5′-CTGAGACCTTATAGGCCCTGTTA-3′; miR-6890-3p: F: 5′-AACGACGAGCAGACAGGAGCAGT-3′, R: 5′-AGCAGCTTTGTACAGGGATATCA-3′; miR-423-5p: F: 5′-TGAGGAGCACGAGACAGCAGGCTAT-3′; R: 5′-CCATCGTGGAGGCTATGCTACAGGCTAT-3′; NA CC1: F: 5′-CCACCCCAGGTCCTTTACC-3′, R: 5′-GGGABCACCTCCTTTTCTC-3′; ATF3: F: 5′-TTGAGAATACTGACGCCTTCT-3′, R: 5′-TGA CGTTCCAGCGAGCAGA-3′; U6: F: 5′-CTCGCTTCGGGAGCACACCGAGG-3′, 5′-AAGCAGCTTTGACCGAA TTGCGT-3′.

Western blot analysis

HCT116 cells or CRC tissues were lysed using 100 mL of radioimmunoprecipitation assay lysis buffer (Solarbio), and protein concentrations were determined using a bicinchoninic acid kit (Boster). Using 10% polyacrylamide gel electrophoresis, the proteins were separated and transferred to a polyvinylidene difluoride membrane (Sigma-Aldrich). Following blocking with 5% bovine serum albumin for one hour, the membrane was incubated with primary antibodies against NACC1 (1:300, ab29047, Abcam), activating-transcription-factor 3 (ATF3; 1:1000, ab254268, Abcam), p63 (1:1000, ab124762, Abcam), B cell leukemia/lymphoma 2 (Bcl-2; 1:1000, ab32124, Abcam), Bcl2 associated X (BAX; 1:1000, ab32503, Abcam), cyclin dependent kinase 2 (CDK2; 1:2000,
ab32147, Abcam), Cyclin A1 (1:1000, ab270940, Abcam), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:10,000, ab8245, Abcam). After three washes in Tris-buffered saline Tween-20, the membranes were treated with secondary anti-rabbit antibody (1:2000, Abcam) for one hour. Gel Imager (Bio-Rad) was used to visualize the immunocomplexes on the membrane using enhanced chemiluminescence reagent. The gray value intensity of the protein bands was analyzed using the ImageJ software. The uncropped gels of Western blotting bands were provided in Supplementary figure 1.

Wound healing migration and Transwell invasion assays

A wound healing assay was performed to detect cell migration. During the wound healing assay, cells were cultured and treated with mitomycin C (10 g/mL) until they reached 80–90% confluence. After 48 hours, cell migration was determined by counting the number of cells that entered the acellular region formed by a sterile insert. For invasion test, Matrigel-coated chambers (BD Biosciences) with 8 μm pores were utilized. In a serum-free medium, $2 \times 10^5$ cells were seeded into the upper chambers coated with Matrigel. The transwell’s lower chamber was filled with culture media containing 10% FBS. After culture for 48 hours at 37°C, non-invaded cells on the top of the transwell were scraped away with a cotton swab. Additionally, cells were fixed with 10% formalin and stained with 0.1% crystal violet before being imaged using a light microscope.

Cell counting kit-8 (CCK-8) assay and apoptosis assay

The CCK-8 test was used to determine cell proliferation. $1 \times 10^3$ cells were seeded into 96-well plates and cultivated for 24, 48, and 72 hours. The CCK-8 solution was then added to a 96-well plate and incubated for additional two hours. At 450 nm, the absorbance

Figure 1. FOXP4-AS1 was highly expressed in CRC cell lines and tissues. A, FOXP4-AS1 expression in different cancers according to the expression profile from GEPIA database; B, FOXP4-AS1 expression in 275 CRC tumor tissues based on the expression profile from GEPIA database; C, The expression of FOXP4-AS1 in the CRC lines HT29, SW620, SW480, LOVO, HCT116 was significantly increased than that in control FHC cell line, which was determined by qRT-PCR, **P < 0.01, Vs. FHC cell line; D, FOXP4-AS1 expression in 38 CRC tissues collected in the present study was determined by qRT-PCR, **P < 0.01, Vs. Adjacent group.
was determined. Flow cytometry was used to detect apoptosis using an Annexin V-FITC and propidium iodide (PI) apoptosis detection kit (Becton Dickinson). We collected 1 × 10^6 cells and suspended them in Annexin-binding buffer. Following that, cells were incubated for 15 minutes at room temperature in the dark with Annexin V-FITC and PI and immediately analyzed using the flow cytometry software equipped in the machine (BD FACSVerse; Becton-Dickinson and Company).

**Cell cycle analysis**

At 48 h of transfection, cells were harvested, fixed with 70% precooled ethanol at 4°C overnight, and stained with 10 μg/ml PI in the dark for half an hour at 37°C. Flow cytometry was performed on the BD FACSCalibur Flow Cytometer system. Cell cycle distribution was analyzed using FlowJo software (version 7.6) and ModFit LT software (version 3.2).

**Bioinformatics analysis**

LncBase (https://carolina.imis.athena-innovation.gr/) was adopted for predicting the miRNAs that binding to lncRNA FOXP4-AS1. The binding site between miR-423-5p and FOXP4-AS1 was also obtained from LncBase. TargetScan (http://www.targetscan.org/vert_71/) was used to predict the targets of miR-423-5p. The binding site of miR-423-5p on NACC1 3'UTR was also obtained from TargetScan. The PROMO database (https://alggen.lsi.upc.es/cgi-bin/promo_v3/) and JASPAR database (https://jaspar.genereg.net/) were used to explore the transcriptional factors that can potentially bind with FOXP4-AS1 promoter.

**Dual-luciferase assay**

The wild-type, and mutant fragments of lncRNA FOXP4-AS1 and 3'-untranslated regions (3'-UTRs) of NACC1 containing the binding sites of miR-423-5p were cloned into the pmirGLO vector to construct the pmirGLO-FOXP4-AS1-Wt/Mut or pmirGLO-NACC1-Wt/Mut vectors. For luciferase assay, 1 × 10^6 cells were seeded in 24-well plates and cultured for 24 h. Following that, using Lipofectamine 3000, the pmirGLO vectors and miR-423-5p mimics were co-transfected into HCT116 cells. After 48 hours, the luciferase activities were determined using the Dual-Luciferase kit (Promega).

**Chromatin immunoprecipitation (ChIP) PCR assay**

CRC cells were crosslinked, lysed, and treated with protease inhibitors. The nuclei were isolated by nuclear separation buffer and cracked by ultrasound. 100 μL supernatant was treated with 60 μL Protein A Agarose/Salmon Sperm DNA containing 900 μL ChIP Dilution Buffer and 20 μL PI for one hour at 4°C. The supernatant was extracted and incubated overnight with 1 μL ATF3 antibody (Abcam). Rabbit IgG acts as a control. The precipitate was then washed consecutively for 10 minutes with 1 mL low, high salt buffer, LiCl solution, and TE solution. 5 M NaCl was added to de-crosslink the DNA, and it was extracted. qRT-PCR was used to quantify the DNA promoter of IncRNA FOXP4-AS1 in the complex. The primer sequence of the IncRNA FOXP4-AS1 promoter region was as follows: F: 5’-GTGAGCT TCTGGGTTGCACA-3', R: 5’-ATTGAGGTTAG GGCAGC-3’.

**Xenograft in nude mice**

Animal experiments were approved by the Institutional Animal Care and Use Committee at the Affiliated Hospital of Nantong University. Eighteen BALB/c nude mice weighing 17–20 g and aged 4–6 weeks were obtained from Vital River Laboratory Co., LTD (Beijing, China) and maintained in a pathogen-free environment. 2 × 10^7 lentivirus infected cells in serum-free DMEM were subcutaneously injected into nude mice that were assigned into the control, Over-FOXP4-AS1, Sh-FOXP4-AS1 groups. At 7, 14, 21, and 28-days following injection, the mice were euthanized by carbon dioxide (100% CO₂ gas replacement rate at 10–30% container volume/min), and the tumors were removed, photographed, and measured with a vernier caliper. The volume of the tumor was determined using the formula (a × b [2])/2, where a denoted length and b denoted width. Tissues from tumors were fixed in 4% paraformaldehyde, embedded, and sectioned into
4 μm sections. The sections were then stained with hematoxylin and eosin (H&E) for 5 minutes.

**Ki-67 immunohistochemistry and terminal deoxynucleotidyl transferase-mediated UTP end-labeling (TUNEL) analysis**

For Ki-67 immunohistochemistry, the sections were incubated with antibodies against Ki-67 (1:200, Abcam) at 4°C overnight. Next, the section was washed three times and incubated with the secondary antibody goat anti-rabbit IgG (H + L). For TUNEL assays, the sections were treated with 0.1% Triton X-100 in 0.1% sodium citrate, and then the sections were incubated for 2 minutes. The section was treated with 50 μL TUNEL reaction mixture and was incubated for 1 hour at 37°C in the dark. Nuclear was stained with 1 mg/mL DAPI, and the images were taken using a fluorescence microscope (Leica, Germany).

**Statistical analysis**

SPSS 21.0 software (IBM Corp., Armonk, New York, USA) was used to analyze the data. The mean and standard deviation of the measurement data were calculated. Multiple group comparisons were conducted using one-way or two-way analysis of variance (ANOVA). The t-test was performed to compare two groups. P < 0.05 was considered significant statistically.

**Results**

**FOXP4-AS1 is highly expressed in CRC cell lines and tissues**

Several studies have observed overexpression of FOXP4-AS1 in CRC tissues than adjacent tissues, suggesting FOXP4-AS1 as an unfavorable prognostic factor. We first evaluated the expression of FOXP4-AS1 in CRC. According to the GEPIA database, lncRNA FOXP4-AS1 was widely expressed in many cancer tissues as compared to normal tissues except adrenocortical carcinoma, kidney renal clear cell carcinoma, acute myeloid leukemia, pheochromocytoma and paraganglioma, and testicular germ cell tumors (Figure 1a). Moreover, the expression of lncRNA FOXP4-AS1 was also dramatically enhanced in the CRC tumor tissues (n = 349), as predicted from GEPIA database (Figure 1b). Furthermore, we found that FOXP4-AS1 expression in the CRC lines HT29, SW620, SW480, LOVO, HCT116 was markedly higher than that in the control FHC cell line (Figure 1c). Additionally, we observed that FOXP4-AS1 expression was considerably higher in 38 CRC tissues than in 38 matched adjacent tissues (Figure 1d). This suggests that lncRNA FOXP4-AS1 might promote CRC progression.

**Overexpression of lncRNA FOXP4-AS1 promotes proliferation, migration, and invasion while inhibiting apoptosis of HCT116 cells**

Effects of FOXP4-AS1 on the proliferation, migration, invasion, and apoptosis of HCT116 cells were evaluated. FOXP4-AS1 overexpressing or silencing vectors were successfully transfected into HCT116 cells (Figure 2a). CCK-8 assay showed that overexpressing lncRNA FOXP4-AS1 promoted HCT116 cell proliferation while suppressing lncRNA FOXP4-AS1 inhibited proliferation of HCT116 cells compared with the control group (Figure 2b). Transwell assay and wound healing assay indicated that overexpression of lncRNA FOXP4-AS1 promoted invasion and migration of HCT116 cells while suppression of lncRNA FOXP4-AS1 inhibited invasion and migration of HCT116 cells compared with the control group (Figure 2c and d). In addition, we found that the apoptosis of HCT116 cells was inhibited significantly in the Over-FOXP4-AS1 group while increased in the sh-FOXP4-AS1 group (Figure 2e). FOXP4-AS1 overexpression decreased p63 and BAX protein expression and increased Bcl-2, CDK2, and Cyclin A1 protein expression. Silencing of FOXP4-AS1 exerts an opposite effect on these proteins (Figure 2f). Moreover, FOXP4-AS1 decreased percentage of cells in the G1 phase and increased percentage of cells in the S phase, while silencing of FOXP4-AS1 exerts the opposite effect (Figure 2g).

**lncRNA FOXP4-AS1 is a molecular sponge for miR-423-5p**

To conform the ceRNA hypothesis in CRC cells, the miRNAs downstream FOXP4-AS1 were searched. To
explore the miRNAs binding to FOXP4-AS1, the DIANA database was used. The results showed that miR-4999-5p, miR-6890-3p, and miR-423-5p showed the highest scores to bind with lncRNA FOXP4-AS1 (Figure 3a). Further analysis showed that miR-423-5p showed the most significant downregulation in 38 CRC tissues compared with the 38 matched adjacent tissues (Figure 3b). Therefore, miR-423-5p was selected for further study. Binding site of miR-423-5p on FOXP4-AS1 was predicted from LncBase. Furthermore, the dual-luciferase reporter system indicated that the relative luciferase activity of pmirGLO-FOXP4-AS1-Wt was lower in the miR-423-5p mimics group than miR-423-5p NC group. However, miR-423-5p mimics caused no significant changes in the relative luciferase activity of pmirGLO-FOXP4-AS1-Mut (Figure 3c). In addition, we found that the expression of miR-423-5p was significantly downregulated by treatment of FOXP4-AS1 overexpressing vector while upregulated by treatment of FOXP4-AS1 silencing vector (Figure 3d).

Figure 2. Overexpression of FOXP4-AS1 promoted proliferation, migration, and invasion while inhibiting apoptosis of HCT116 cells. A, FOXP4-AS1 was overexpressed or knocked down in HCT116 cells; B, CCK-8 assay was utilized to analyze the proliferation of HCT116 cells under the condition of FOXP4-AS1 overexpression or silencing; C and D, Transwell assay and wound healing assay were performed to detect the invasion and migration of HCT116 cells after transfection with pcDNA3.1-FOXP4-AS1 or sh-FOXP4-AS1, respectively; E, The apoptosis of HCT116 cells was detected by flow cytometry analysis; F, The protein expression of p63, Bcl-2, BAX, CDK2, and Cyclin A1 in HCT116 cells was revealed by Western blotting; G, Analysis on cell cycle distribution was performed using flow cytometry. Data were presented as mean ± SD, *P < 0.05, **P < 0.01, Over-FOXP4-AS1 or Sh-FOXP4-AS1 Vs. Control group.
miR-423-5p proliferation, migration, invasion, and apoptosis of HCT116 cells

To reveal the function of the FOXP4-AS1/miR-423-5p axis in CRC, rescue experiments were conducted subsequently. MiR-423-5p expression was increased by miR-423-5p mimics and decreased by miR-423-5p inhibitor, which was rescued by pcDNA3.1-FOXP4-AS1 and sh-FOXP4-AS1, respectively (Figure 4a). CCK-8 assay showed that the proliferation of HCT116 cells was reduced by miR-423-5p mimics and promoted by miR-423-5p inhibitor, compared with the miR-423-5p NC control group (Figure 4b). Transwell and wound healing assay indicated that miR-423-5p mimics inhibited invasion and migration of HCT116 cells while miR-423-5p inhibitor promoted invasion and migration of HCT116 cells (Figure 4c and d). Moreover, flow cytometry showed that number of apoptotic cells significantly increased by miR-423-5p mimics and decreased by miR-423-5p inhibitor (Figure 4e). MiR-423-5p mimics promoted p63 and BAX protein expression and suppressed Bcl-2, CDK2, and Cyclin A1 protein expression. Adverse changes on these proteins were caused by miR-423-5p inhibitor (Figure 4f). Furthermore, miR-423-5p mimics increased percentage of cells in the G1 phase and decreased percentage of cells in the S phase, while miR-423-5p inhibitor caused the adverse changes on cell distribution (Figure 4g). In addition, we found that the function of miR-423-5p on the proliferation, invasion, migration, apoptosis, and cell cycle arrest of HCT116 cells could be reversed by FOXP4-AS1.

NACC1 is a direct target of miR-423-5p

Targets of miR-423-5p in CRC were explored. TargetScan was used to predict the targets of miR-423-5p. The results showed that NACC1 is one of the targets of miR-423-5p, which has the binding site at the position 379–386 of NACC1 3’UTR, suggesting that miR-423-5p could bind to NACC1.
Figure 4. Knockdown of miR-423-5p promoted proliferation, migration, and invasion while inhibiting apoptosis of HCT116 cells. A. The expression of miR-423-5p in HCT116 cells after transfections was detected by qRT-PCR. B, CCK-8 assay was performed to analyze effects of miR-423-5p and FOXP4-AS1 on HCT116 cell proliferation; C and D, Transwell assay and wound healing assay was performed to detect the HCT116 cell invasion and migration, respectively; E, The effects of miR-423-5p and FOXP4-AS1 on apoptosis of HCT116 cells was detected by flow cytometry; F, The protein expression of p63, Bcl-2, BAX, CDK2, and Cyclin A1 in HCT116 cells was revealed by Western blotting; G, Analysis on cell cycle distribution was performed using flow cytometry. Data was presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, miR-423-5p mimics Vs. miR-423-5p NC group; #P < 0.05, ##P < 0.01, miR-423-5p inhibitor Vs. miR-423-5 NC group; @P < 0.05, @@P < 0.01, @@@P < 0.001 miR-423-5p mimics + Over-lnc Vs. miR-423-5p mimics group; &P < 0.05, &&P < 0.01, miR-423-5p inhibitor + Sh-lnc Vs. miR-423-5p inhibitor group.

(Figure 5a). qRT-PCR analysis and Western blot analysis showed that the expression of NACC1 was significantly upregulated in 38 CRC tumor tissues compared with 38 matched adjacent tissues (Figure 5b and c). Dual-luciferase reporter system analysis revealed that the relative luciferase activity of pmirGLO- NACC1-Wt was significantly decreased in the miR-423-5p mimics group compared with the miR-423-5p NC group. However, no apparent changes were observed in the mutant group (Figure 5d). In addition, we found that the expression of
NACC1 was significantly decreased in the miR-423-5p mimics group and increased in the miR-423-5p inhibitor group (Figure 5e and f).

**MiR-423-5p-controlled NACC1 promotes proliferation, migration, and invasion while inhibiting apoptosis of HCT116 cells**

Functions of NACC1 in HCT116 cells were investigated. The expression of NACC1 was successfully overexpressed or suppressed by pcDNA3.1-NACC1 and Sh-NACC1 plasmids, respectively (Figure 6a and b). CCK-8 assay showed that overexpressing NACC1 promoted the proliferation of HCT116 cells while suppressing NACC1 inhibited HCT116 cell proliferation (Figure 6c). Transwell assay and wound healing assay indicated that overexpression of NACC1 promoted invasion and migration of HCT116 cells while suppression of NACC1 inhibited invasion and migration of HCT116 cells (Figure 6d and e). In addition, we found that the apoptosis of HCT116 cells was significantly inhibited in the Over-NACC1 group while increased in the Sh-NACC1 group (Figure 6f). p63 and BAX protein expression was decreased by NACC1 overexpression and increased by NACC1 knockdown. Bcl-2, CDK2, and Cyclin A1 protein expression was increased by NACC1 overexpression and decreased by NACC1 inhibition. (Figure 6g). Moreover, NACC1 decreased percentage of cells in the G1 phase and increased percentage of cells in the S phase, while silencing of NACC1 exerts the opposite effect (Figure 6h). However, the function of NACC1 on the HCT116 cells could be partially reversed by miR-423-5p, suggesting that miR-423-5p exerts its function in HCT116 cells by NACC1.

**FOXP4-AS1 promotes CRC progression in vivo**

The function of FOXP4-AS1 on CRC progression in mice also investigated. As shown in Figure 7a, the expression of FOXP4-AS1 was significantly upregulated or downregulated in mice tumors by injection of lentivirus-infected cells expressing FOXP4-AS1 or sh-FOXP4-AS1. Further analysis showed that the
Figure 6. Overexpressing NACC1 promoted proliferation, migration, and invasion while inhibiting apoptosis of HCT116 cells regulated by miR-423-5p. A and B. The expression of NACC1 was successfully overexpressed or suppressed by pcDNA3.1-NACC1 and Sh-NACC1 plasmids, as detected by qRT-PCR and Western blot, respectively; C, CCK-8 analysis was used to detect the effects of NACC1 and miR-423-5p on proliferation of HCT116 cells; D and E, Transwell assay and wound healing assay were used to detect the invasion and migration of HCT116 cells, respectively; F, The apoptosis of HCT116 cells was detected by flow cytometry; G, The protein expression of p63, Bcl-2, BAX, CDK2, and Cyclin A1 in HCT116 cells was revealed by Western blotting; H, Analysis on cell cycle distribution was performed using flow cytometry. Data was presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, Over-NACC1 Vs. Control group; #P < 0.05, ##P < 0.01, ###P < 0.001, Over-NACC1 + miR-423-5p mimics Vs. Over-NACC1 group; @P < 0.05, @@P < 0.01, @@@P < 0.001, Sh-NACC1 Vs. Control group; &P < 0.05, &&P < 0.01, &&&P < 0.001, Sh-NACC1 + miR-423-5p inhibitor Vs. Sh-NACC1 group.

tumor volume was significantly larger in FOXP4-AS1 overexpressing group and smaller in FOXP4-AS1 silencing group (Figure 7b). H&E staining assay indicated that overexpressing FOXP4-AS1 increased the inflammatory cell infiltration in the tumor tissue while suppressing FOXP4-AS1 reduced the inflammatory cell infiltration (Figure 7c). Furthermore, we found that overexpression of FOXP4-AS1
Figure 7. FOXP4-AS1 promoted CRC tumor growth and metastasis in vivo. A, The expression of FOXP4-AS1 was significantly upregulated or downregulated in vivo; B, Tumor volume affected by FOXP4-AS1; C, H&E analysis was used to detect the effects of FOXP4-AS1 on inflammatory cell infiltration in the tumor tissues; D and E, Ki-67 immunohistochemical staining and TUNEL were used to detect the proliferation and apoptosis of tumor cells affected by FOXP4-AS1 in vivo; F, The expression of miR-423-5p was detected by qRT-PCR affected by FOXP4-AS1 in vivo; G, The expression changes of NACC1 affected by FOXP4-AS1 was detected by Western blot, Data was presented as mean ± SD, **P < 0.01 Over-FOXP4-AS1 Vs. Control group, ##P < 0.01, Sh-FOXP4-AS1Vs. Control group.

significantly elevated tumor cell proliferation while inhibiting apoptosis compared with the NC group (Figure 7d and e). Meanwhile, the opposite results were observed in suppressing overexpressing the FOXP4-AS1 group (Figure 7d and e). In addition, we found that the expression of miR-423-5p was significantly downregulated when overexpressing FOXP4-AS1 but upregulated when suppressing FOXP4-AS1 (Figure 7f). Compared with miR-423-5p, expression of NACC1 showed opposite responses to FOXP4-AS1 (Figure 7g).

**Upregulation of FOXP4-AS1 is activated by ATF3 in CRC cells**

Transcription factors play crucial roles in activating gene expression by binding with the promoter of target genes. We explored the transcription factors for FOXP4-AS1 in CRC cells. The PROMO database and JASPAR database were used to explore the transcriptional factors that can potentially bind with FOXP4-AS1 promoter. DNA motif of ATF3 and score of ATF3 to bind to the promoter of FOXP4-AS1 were obtained from JASPAR database (Figure 8a). The ChIP-PCR assay revealed that FOXP4-AS1 was significantly enriched in the anti-ATF3 group compared with the IgG group (Figure 8b). Dual-luciferase reporter system indicated that the luciferase activity of vectors containing wild type FOXP4-AS1 promoter was significantly increased in ATF3 group, while that of vectors containing mutant FOXP4-AS1 promoter presented no significant changes (Figure 8c). In addition, we found that pcDNA3.1-ATF3 markedly increased FOXP4-AS1 expression while sh-ATF3 decreased the expression of FOXP4-AS1 compared with the control group (Figure 8d).

**Discussion**

The pathogenesis of CRC is still unclear, and it is currently considered as the result of the long-term effect of environmental factors and genetic characteristics [20]. Several genes play a role in the initiation and progression of colorectal cancer [21]. Therefore, the mechanism of CRC progression needs to be investigated. In the present study,
Figure 8. Upregulation of FOXP4-AS1 is activated by ATF3 in CRC cells. A, PROMO database (https://alggen.lsi.upc.es/cgi-bin/promo_v3/) and JASPAR database (https://jaspar.genereg.net/) were used to explore binding site between the promoter of FOXP4-AS1 and transcriptional factor ATF3; B, ChIP-PCR assay was used to detect the expression of FOXP4-AS1 in anti-ATF3 group and IgG group, **P < 0.01, anti-ATF3 Vs. anti-IgG group; C, Dual-luciferase reporter system was used to detect the binding of ATF3 to FOXP4-AS1 promoter; D, The effect of ATF3 on expression of FOXP4-AS1 was detected by qRT-PCR, **P < 0.01 Over-ATF3 Vs. Over-NC group; **P < 0.01, Sh-ATF3 Vs. Over-NC group.
we demonstrated that FOXP4-AS1 was expressed highly in CRC cell lines and tissues, and overexpression of FOXP4-AS1 promoted CRC progression both in vitro and in vivo. Mechanically, we demonstrated that ATF3 promoted FOXP4-AS1 expression, which exacerbates colorectal cancer progression via the miR-423-5p/NACC1 axis.

LncRNAs are widely involved in critical biological functions in life activities, such as the development and differentiation of individual organisms, reproduction, apoptosis, cell reprogramming, et al., and are closely related to human diseases and CRC [22–24]. FOXP4-AS1 has been identified as a prognostic biomarker for CRC based on bioinformatics analysis [18]. Furthermore, Juan Li et al. revealed that FOXP4-AS1 is a functional oncogene in CRC pathogenesis by promoting cancer cell proliferation and suppressing apoptosis. They also generated animal tumor xenografts and revealed that FOXP4-AS1 promotes tumor growth in vivo [17]. Based on these studies, we further confirmed the oncogenic role of FOXP4-AS1 in CRC by adding more evidence, for example, it was indicated that FOXP4-AS1 promoted cancer cell migration and invasion. Both FOXP4-AS1 overexpressing and silencing vectors were used for the functional assays, which further confirms our findings. More importantly, the present study innovatively revealed the underlying ceRNA pathway mediated by FOXP4-AS1 in CRC.

The present study found that FOXP4-AS1 is a molecular sponge for miR-423-5p, and NACC1 is a direct target of miR-423-5p. Serum miR-423-5p expression is significantly elevated in patients with stage I–II CRC compared with the control [25]. Inversely, concentration of plasma miR-423-5p is decreased in patients with CRC [26]. Furthermore, Shang et al. revealed miR-423-5p as a contributor in controlling colorectal cancer cell radiosensitivity, indicating miR-423-5p as a molecular candidate for radiation-combined therapy to treat colorectal cancer [27]. We revealed the downregulation of miR-423-5p in 38 CRC tissues. Knockdown of miR-423-5p enhanced proliferation, migration, and invasion while inhibiting the apoptosis of HCT116 cells.

NACC1 has been indicated to contribute to tumor progression in different cancers, such as lung adenocarcinoma, mantle cell lymphoma, and ovarian cancer [28–30]. In this investigation, we found that NACC1 is a target downstream miR-423-5p and is degraded by it. FOXP4-AS1 enhances NACC1 expression by binding with miR-423-5p. NACC1 promotes proliferation, migration and invasion, inhibits apoptosis of HCT116 cells, while these effects were rescued by miR-423-5p, indicating that the tumor-facilitator role of NACC1 in CRC was regulated by miR-423-5p. Furthermore, a previous study revealed that NACC1 transcriptionally activates HOXA9 in CRC cells and regulates CRC cell apoptosis by increasing expression of HOXA9 [31]. HOXA9 is a widely acknowledged oncogene in CRC [32,33]. It can be inferred that NACC1 works in CRC by activating HOXA9.

Transcription factors regulate genes by binding cis-acting elements in their promoter regions. Increasing numbers of transcription factors were found to play essential roles in CRC, such as IRF1, BTF3, and STAT3 [34–36]. FOXP4-AS1 can be transcriptionally activated by paired box 5 [37] and Yin Yang 1 [38]. In the present study, we found that upregulation of FOXP4-AS1 activated by ATF3 in CRC cells. Several studies have indicated that ATFs act as an oncogene in CRC, for example, the induction of ATF3 contributes to anti-cancer activity of Abeliophyllum distichum Nakai in human CRC cells [39]. Yan et al. showed that overexpression of ATF3 promotes the pathogenic development of CRC [40]. To sum up, these results demonstrated that ATF3 activated FOXP4-AS1 aggravates the progression of colorectal cancer by regulating the miR-423-5p/NACC1 axis.

However, some limitations of the present study must be addressed. First, the functions of the miR-423-5p/NACC1 axis in vivo need investigation. Second, the limited clinical sample size restricts the conviction of the present study to some degree. Third, the animal experiments lack the evidence to show the effects of FOXP4-AS1 on liver and lung metastasis in CRC. Moreover, there are some other axes that might be regulated by FOXP4-AS1 in CRC by the ceRNA pathway, and more miRNAs controlled by FOXP4-AS1 in CRC progression deserve further studies.

**Conclusion**

In summary, we demonstrated that FOXP4-AS1 is highly expressed in CRC cell lines and tissues, and overexpression of FOXP4-AS1 promotes CRC
progression both in vitro and in vivo. Mechanically, we revealed that ATF3-induced FOXP4-AS1 aggravates the progression of CRC by regulating the miR-423-5p/NACC1 axis. These findings provide a solid theoretical foundation for applying FOXP4-AS1 on the diagnosis and treatment of CRC.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

The research was supported by (1) The fifth "333 High-level Talents Training Project" of Jiangsu Department of Science and Technology (BRA2020397); and (2) General project of National Natural Science Foundation of China (82173270).

**References**

[1] Zaborowski AM, Winter DC, Lynch L. The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. Br J Cancer. 2021;125 (10):1341–1349.

[2] El Bali M, Bakkach J, Bennani Mechita M. Colorectal cancer: from genetic landscape to targeted therapy. J Oncol. 2021;2021:9918116.

[3] Xu L, Zhang C, Yin H, et al. RNA modifications act as regulators of cell death. RNA Biol. 2021 Dec;182:2183–2193. doi:10.1080/15476286.2021.1925460.

[4] Sellitto A, Pecoraro G, Giurato G, et al. Regulation of metabolic reprogramming by long non-coding RNAs in cancer. Cancers (Basel). 2021;13(14): 3485. doi:10.3390/cancers13143485.

[5] Chowdhary A, Satagopam V, Schneider R. Long non-coding RNAs: mechanisms, experimental, and computational approaches in identification, characterization, and their biomarker potential in cancer. Front Genet. 2021;12:649619.

[6] Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci. 2020;21(15): 5311. doi:10.3390/ijms21155311.

[7] Wang X, Lai Q, He J, et al. LncRNA SNHG6 promotes proliferation, invasion and migration in colorectal cancer cells by activating TGF-beta/Smad signaling pathway via targeting UPF1 and inducing EMT via regulation of ZEB1. Int J Med Sci. 2019;16(1):51–59.

[8] Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m (6)A reader YTHDF3. Mol Cancer. 2019;18(1):143.

[9] Xu W, Zhou G, Wang H, et al. Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer. Int J Cancer. 2020;146 (10):2901–2912.

[10] Galamb O, Bartak BK, Kalmar A, et al. Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J Gastroenterol. 2019;25(34):5026–5048.

[11] Baassiri A, Nassar F, Mukherji D, et al. Exosomal non coding RNA in LIQUID biopsies as a promising biomarker for colorectal cancer. Int J Mol Sci. 2020;21(4): 1398. doi:10.3390/ijms21041398.

[12] Wang AH, Fan WJ, Fu L, et al. LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. Eur Rev Med Pharmacol Sci. 2019;23:8310–8320.

[13] Zheng Y, Zeng J, Xia H, et al. Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis. Bioengineered. 2021;12(1):5476–5490.

[14] Yu Z, Wang Y, Deng J, et al. Long non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axis. Bioengineered. 2021;12(1):6251–6263.

[15] Shi Z, Shen C, Yu C, et al. Long non-coding RNA LINC00997 silencing inhibits the progression and metastasis of colorectal cancer by sponging miR-512-3p. Bioengineered. 2021;12(1):627–639.

[16] Ghasemi T, Khalaj-Kondori M, Hosseinpour Feizi MA, et al. lncRNA-miRNA-mRNA interaction network for colorectal cancer; An in silico analysis. Comput Biol Chem. 2020;89:107370.

[17] Li J, Lian Y, Yan C, et al. Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer. Cell Prolif. 2017;50(1):e12312. doi:10.1111/cpr.12312.

[18] Shi ZL, Zhou GQ, Guo J, et al. Identification of a prognostic colorectal cancer model including LncRNA FOXP4-AS1 and LncRNA BBOX1-AS1 based on bioinformatics analysis. Cancer Biother Radiopharm. 2021. DOI:10.1089/cbr.2020.4242.

[19] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25 (4):402–408.

[20] Chan DKH, Buczacki SJA. Tumour heterogeneity and evolutionary dynamics in colorectal cancer. Oncogenesis. 2021;10(7):53.

[21] Pallan A, Dedelaite M, Mirijkar N, et al. Postoperative complications of colorectal cancer. Clin Radiol. 2021;76 (12):896–907.

[22] Sun P, Quan JC, Wang S, et al. LncRNA-PACER upregulates COX-2 and PGE2 through the NF-kB pathway to
promote the proliferation and invasion of colorectal-cancer cells. Gastroenterol Rep (Oxf). 2021;9(3):257–268.

[23] Zhao S, Guan B, Mi Y, et al. LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit. Oncogene. 2021;40(28):4709–4724.

[24] Ghasemian M, Rajabibazl M, Mirfakhraie R, et al. Long noncoding RNA LINC00978 acts as a potential diagnostic biomarker in patients with colorectal cancer. Exp Mol Pathol. 2021;122:104666.

[25] Lu J, Lu J. The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. Clin Lab. 2015;61(01+02/2015):187–190.

[26] Fang Z, Tang J, Bai Y, et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res. 2015;34(1):86.

[27] Shang Y, Wang L, Zhu Z, et al. Downregulation of miR-423-5p contributes to the radioresistance in colorectal cancer cells. Front Oncol. 2020;10:582239.

[28] Sun Z. Circular RNA hsa_circ_0001588 promotes the malignant progression of lung adenocarcinoma by modulating miR-524-3p/NACC1 signaling. Life Sci. 2020;259:118157.

[29] Tao HF, Shen JX, Hou ZW, et al. LncRNA FOXP4AS1 predicts poor prognosis and accelerates the progression of mantle cell lymphoma through the miR4235p/NACC1 pathway. Oncol Rep. 2021;45:469–480.

[30] Du W, Feng Z, Sun Q. LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway. Biochem Biophys Res Commun. 2018;507(1–4):198–202.

[31] Ju T, Jin H, Ying R, et al. Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells. Mol Med Rep. 2017;16(3):3194–3200.

[32] Watanabe Y, Saito M, Saito K, et al. Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett. 2018;15(3):2756–2762.

[33] Bhatlekar S, Viswanathan V, Fields JZ, et al. Overexpression of HOXA4 and HOXA9 genes promotes self-renewal and contributes to colon cancer stem cell overpopulation. J Cell Physiol. 2018;233(2):727–735.

[34] Wright G, Sonavane M, Gassman NR. Activated STAT3 is a novel regulator of the XRCC1 promoter and selectively increases XRCC1 protein levels in triple negative breast cancer. Int J Mol Sci. 2021;22(11):5475. doi:10.3390/ijms22115475.

[35] Zhou W, Yun Z, Wang T, et al. BTF3-mediated regulation of BMI1 promotes colorectal cancer through influencing epithelial-mesenchymal transition and stem cell-like traits. Int J Biol Macromol. 2021; 187:800–810. doi:10.1016/j.ijbiomac.2021.07.106.

[36] Yuan L, Zhang X, Cheng K, et al. IRF1 inhibits autophagy-mediated proliferation of colorectal cancer via targeting ATG13. Cancer Invest. 2021;1–18. DOI:10.1080/07357907.2021.1961265.

[37] Wu X, Xiao Y, Zhou Y, et al. LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4. Cell Death Dis. 2019;10(7):472.

[38] Li Y, Li T, Yang Y, et al. YY1-induced upregulation of FOXP4-AS1 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells. Cell Biol Int. 2020;44(7):1447–1457.

[39] Park GH, Park JH, Eo HJ, et al. The induction of activating transcription factor 3 (ATF3) contributes to anti-cancer activity of Abeliophyllum distichum Nakai in human colorectal cancer cells. BMC Complement Altern Med. 2014;14(1):487.

[40] Yan F, Ying L, Li X, et al. Overexpression of the transcription factor ATF3 with a regulatory molecular signature associates with the pathogenic development of colorectal cancer. Oncotarget. 2017;8(29):47020–47036.